Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03601936 · ClinicalTrials.gov registry record · NA
User Testing of the Evivo Screening Test
A NA study, sponsored by Evolve BioSystems.
- Terminated
- Registry status
- NA
- Development phase
- 231
- Enrollment target
NCT03601936: Clinical Trial NA study, sponsored by Evolve BioSystems.
NCT03601936 is a NA study that was terminated before completion, run by Evolve BioSystems. The registered enrollment target is 231 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03601936, a NA study, was terminated before completion, sponsored by Evolve BioSystems.
- TERMINATED
- Registry status
- NA
- Development phase
- 231 participants
- Enrollment target
Study Summary
The study is an evaluation of the Evivo Screening Test's ability to differentiate between high and low levels of Bifidobacterium in infant stool specimens.
Primary Outcome
The primary objective of this CLIA Waiver User Testing study is to evaluate the performance of the Evivo Infant Gut Bifidobacterium Screening Test in a setting that closely resembles the conditions of intended use, specifically the circumstances of sample collection, the location of test sites, and the potential operators.
Interventions
- DEVICE Evivo Infant Gut Bifidobacterium Screening Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2019-04-24 |
| Phase | NA |
Why NCT03601936 stopped before completion
NCT03601936 is an interventional study that assigns participants to a tested intervention. The registered 231 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 1 intervention - of which Evivo Infant Gut Bifidobacterium Screening Test is the first listed.
NCT03601936 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03601936 about?
NCT03601936 is a clinical study titled "User Testing of the Evivo Screening Test". The study is an evaluation of the Evivo Screening Test's ability to differentiate between high and low levels of Bifidobacterium in infant stool specimens.
What is the current status of trial NCT03601936?
This trial is currently terminated. It is a NA study. The enrollment target is 231 participants. The study started on 2018-08-01. Estimated completion is 2019-04-24.
What interventions are being tested in trial NCT03601936?
The interventions under investigation include: Evivo Infant Gut Bifidobacterium Screening Test (DEVICE).
Who is sponsoring clinical trial NCT03601936?
This trial is sponsored by Evolve BioSystems, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03601936's enrollment target sits among peer trials
231 465th of 2000 higher than 1,536 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04077099 · 231 participants · Phase 1
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
- NCT05019495 · 231 participants · NA
Optimizing Tobacco Treatment Delivery for People Living With HIV
- NCT06023589 · 231 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
- NCT06734351 · 231 participants · Phase 3
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI